• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

程序性死亡受体配体1（PD-L1）和细胞毒性T淋巴细胞相关抗原4（CTLA-4）在女性尿道癌中的表达。

Expression of PD-L1 and CTLA-4 in female urethral carcinoma.

作者信息

Ninomiya Sahoko, Kawahara Takashi, Mochizuki Taku, Ishiguro Yukari, Miyoshi Yasuhide, Otani Masako, Yao Masahiro, Miyamoto Hiroshi, Uemura Hiroji

机构信息

Departments of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Kanagawa Japan.

Division of Diagnostic Pathology Yokohama City University Medical Center Yokohama Kanagawa Japan.

出版信息

IJU Case Rep. 2018 Nov 23;2(1):23-26. doi: 10.1002/iju5.12029. eCollection 2019 Jan.

DOI:10.1002/iju5.12029
PMID:32743365
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7292119/
Abstract

INTRODUCTION

Although the tumors are often easily detected, a considerable number of patients with female urethral carcinoma are diagnosed in an advance stage. Thus, no evidence-based therapeutic approach has been established. We herein report our experience in the treatment of three female patients with urethral carcinoma. We also examined the expression of PD-L1 and CTLA-4.

CASE PRESENTATION

Three female patients pathologically diagnosed with urethral carcinoma, including urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma, between 2013 and 2017 were analyzed in this study. Two patients underwent urethrectomy with cystostomy. Immunohistochemistry was performed to assess the levels of PD-L1 and CTLA-4 expression in patients with urethral carcinoma. Eleven control cases of urethral carcinoma tissue were also stained.

CONCLUSION

This study revealed the expression of PD-L1 and CTLA-4 in female urethral carcinomas.

摘要

引言

尽管肿瘤通常易于检测，但相当数量的女性尿道癌患者在晚期才被诊断出来。因此，尚未建立基于证据的治疗方法。我们在此报告我们治疗三名女性尿道癌患者的经验。我们还检测了程序性死亡受体1（PD-L1）和细胞毒性T淋巴细胞相关蛋白4（CTLA-4）的表达情况。

病例介绍

本研究分析了2013年至2017年间经病理诊断为尿道癌的三名女性患者，包括尿路上皮癌、鳞状细胞癌和腺癌。两名患者接受了尿道切除术及膀胱造瘘术。采用免疫组织化学法评估尿道癌患者中PD-L1和CTLA-4的表达水平。同时对11例尿道癌组织对照病例进行了染色。

结论

本研究揭示了PD-L1和CTLA-4在女性尿道癌中的表达情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec4/7292119/7b0038701e79/IJU5-2-23-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec4/7292119/27df25e3288f/IJU5-2-23-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec4/7292119/5495a5953138/IJU5-2-23-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec4/7292119/7b0038701e79/IJU5-2-23-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec4/7292119/27df25e3288f/IJU5-2-23-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec4/7292119/5495a5953138/IJU5-2-23-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec4/7292119/7b0038701e79/IJU5-2-23-g003.jpg

相似文献

1
Expression of PD-L1 and CTLA-4 in female urethral carcinoma.程序性死亡受体配体1（PD-L1）和细胞毒性T淋巴细胞相关抗原4（CTLA-4）在女性尿道癌中的表达。
IJU Case Rep. 2018 Nov 23;2(1):23-26. doi: 10.1002/iju5.12029. eCollection 2019 Jan.
2
Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.免疫检查点调节剂、细胞毒性 T 淋巴细胞抗原 4（CTLA-4）和程序性死亡配体 1（PD-L1）在女性乳腺癌中的表达。
PLoS One. 2018 Apr 19;13(4):e0195958. doi: 10.1371/journal.pone.0195958. eCollection 2018.
3
PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas.马阴茎鳞状细胞癌中PD-L1/PD-1和CTLA-4的表达
Animals (Basel). 2021 Jul 16;11(7):2121. doi: 10.3390/ani11072121.
4
The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.子宫颈癌中的免疫检查点CTLA-4和PD-L1
Pathol Res Pract. 2020 Jan;216(1):152782. doi: 10.1016/j.prp.2019.152782. Epub 2019 Dec 9.
5
Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.非小细胞肺癌患者中PD-1、PD-L1和CTLA-4基因表达与临床病理特征的相关性
Clin Lung Cancer. 2017 Mar;18(2):e109-e116. doi: 10.1016/j.cllc.2016.09.010. Epub 2016 Oct 17.
6
Histopathological Subtypes and PD-L1 Expression in Primary Urethral Adenocarcinoma: A Series of 5 Cases.原发性尿道腺癌的组织病理学亚型和 PD-L1 表达：5 例系列研究。
Int J Surg Pathol. 2021 Aug;29(5):488-495. doi: 10.1177/1066896920988348. Epub 2021 Jan 19.
7
Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.免疫检查点调节剂、细胞毒性 T 淋巴细胞抗原 4 和程序性死亡配体 1 在 Epstein-Barr 病毒相关鼻咽癌中的表达。
Appl Immunohistochem Mol Morphol. 2021 Jul 1;29(6):401-408. doi: 10.1097/PAI.0000000000000903.
8
PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.PD-L1 在肿瘤细胞和膀胱癌免疫微环境中的表达：165 例病例的病理回顾。
Hum Pathol. 2018 Nov;81:184-191. doi: 10.1016/j.humpath.2018.06.028. Epub 2018 Jun 30.
9
Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.胃腺癌中免疫检查点程序性死亡1配体1和细胞毒性T淋巴细胞相关分子4
Oncoimmunology. 2015 Nov 9;5(5):e1100789. doi: 10.1080/2162402X.2015.1100789. eCollection 2016 May.
10
Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression.胃癌中的细胞毒性 T 淋巴细胞相关蛋白 4：预后与 PD-L1 表达的相关性。
J Surg Oncol. 2021 Dec;124(7):1040-1050. doi: 10.1002/jso.26604. Epub 2021 Jul 13.

引用本文的文献

1
Chemotherapy combined with immunotherapy in primary female urethral squamous cell carcinoma: a case report.原发性女性尿道鳞癌化疗联合免疫治疗 1 例报告
J Int Med Res. 2022 Oct;50(10):3000605221132418. doi: 10.1177/03000605221132418.

本文引用的文献

1
Expression of receptor activator of nuclear factor kappa B ligand in bladder cancer.核因子κB配体受体激活剂在膀胱癌中的表达
Int J Urol. 2018 Oct;25(10):901-902. doi: 10.1111/iju.13756. Epub 2018 Jul 24.
2
Primary urethral carcinoma: A Surveillance, Epidemiology, and End Results data analysis identifying predictors of cancer-specific survival.原发性尿道癌：一项监测、流行病学和最终结果数据分析，确定癌症特异性生存的预测因素。
Urol Ann. 2018 Apr-Jun;10(2):170-174. doi: 10.4103/UA.UA_136_17.
3
Skene duct adenocarcinoma in a patient with an elevated serum prostate-specific antigen level: a case report.
血清前列腺特异性抗原水平升高患者的斯基恩氏腺腺癌：一例报告
J Med Case Rep. 2018 Feb 14;12(1):32. doi: 10.1186/s13256-017-1558-y.
4
Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.检查点抑制剂：治疗尿路上皮膀胱癌的新模式。
Med Oncol. 2017 Sep 1;34(10):170. doi: 10.1007/s12032-017-1029-8.
5
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.美国食品药品监督管理局批准摘要：阿替利珠单抗用于治疗含铂化疗后进展期晚期尿路上皮癌患者。
Oncologist. 2017 Jun;22(6):743-749. doi: 10.1634/theoncologist.2017-0087. Epub 2017 Apr 19.
6
Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA.美国膀胱癌腺癌的当代病理特征和死亡率
Int J Urol. 2017 Feb;24(2):117-123. doi: 10.1111/iju.13261. Epub 2016 Nov 22.
7
EAU guidelines on primary urethral carcinoma.EAU 指南：原发性尿道癌
Eur Urol. 2013 Nov;64(5):823-30. doi: 10.1016/j.eururo.2013.03.044. Epub 2013 Apr 2.